Pharmacotherapy of heart failure

Amberkar Mohanbabu Vittalrao, Harish Thanusubramanian, K. Meena Kumari, Arshad Basha Shaik

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Heart failure (HF) is one of the major problems related to heart diseases in the modern era. Multiple comorbidities such as coronary artery disease, hypertension, diabetes mellitus, and anemia have a great contribution in the development of HF. It is primarily two types systolic and diastolic HF. Insufficient or decreased pumping of the heart is systolic HF, whereas diastolic HF is because of lack of ability of the heart to relax or increased muscle inflexibility. The pathophysiology of HF is due to enhanced activity of sympathetic system, renin angiotensin system, and structural changes in the wall of ventricle. The two definite targets of medical treatment in HF are as follows: (1) Alleviation of obstructive (or) decreased output manifestations and replenishment of cardiac function. The drugs used are frusemide, thiazides, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), amrinone/milrinone, dopamine/dobutamine, levosimendan, digoxin, hydralazine, nitroprusside, nitrate, bisoprolol, metoprolol, nebivolol, and carvedilol. (2) Prevention of advancement of HF and extension of patient survival-drugs used are β blockers, ACE inhibitors/ARBs, spironolactone, and eplerenone.

Original languageEnglish
Pages (from-to)78-87
Number of pages10
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume11
Issue number6
DOIs
Publication statusPublished - 01-06-2018

Fingerprint

Heart Failure
Drug Therapy
Diastolic Heart Failure
Systolic Heart Failure
Angiotensin Receptor Antagonists
Nebivolol
Angiotensin-Converting Enzyme Inhibitors
Amrinone
Bisoprolol
Milrinone
Thiazides
Hydralazine
Spironolactone
Metoprolol
Dobutamine
Digoxin
Furosemide
Nitroprusside
Renin-Angiotensin System
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Vittalrao, Amberkar Mohanbabu ; Thanusubramanian, Harish ; Meena Kumari, K. ; Shaik, Arshad Basha. / Pharmacotherapy of heart failure. In: Asian Journal of Pharmaceutical and Clinical Research. 2018 ; Vol. 11, No. 6. pp. 78-87.
@article{7d6db2cc7d4d4fe0baa93506e326f405,
title = "Pharmacotherapy of heart failure",
abstract = "Heart failure (HF) is one of the major problems related to heart diseases in the modern era. Multiple comorbidities such as coronary artery disease, hypertension, diabetes mellitus, and anemia have a great contribution in the development of HF. It is primarily two types systolic and diastolic HF. Insufficient or decreased pumping of the heart is systolic HF, whereas diastolic HF is because of lack of ability of the heart to relax or increased muscle inflexibility. The pathophysiology of HF is due to enhanced activity of sympathetic system, renin angiotensin system, and structural changes in the wall of ventricle. The two definite targets of medical treatment in HF are as follows: (1) Alleviation of obstructive (or) decreased output manifestations and replenishment of cardiac function. The drugs used are frusemide, thiazides, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), amrinone/milrinone, dopamine/dobutamine, levosimendan, digoxin, hydralazine, nitroprusside, nitrate, bisoprolol, metoprolol, nebivolol, and carvedilol. (2) Prevention of advancement of HF and extension of patient survival-drugs used are β blockers, ACE inhibitors/ARBs, spironolactone, and eplerenone.",
author = "Vittalrao, {Amberkar Mohanbabu} and Harish Thanusubramanian and {Meena Kumari}, K. and Shaik, {Arshad Basha}",
year = "2018",
month = "6",
day = "1",
doi = "10.22159/ajpcr.2018.v11i6.23712",
language = "English",
volume = "11",
pages = "78--87",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "6",

}

Pharmacotherapy of heart failure. / Vittalrao, Amberkar Mohanbabu; Thanusubramanian, Harish; Meena Kumari, K.; Shaik, Arshad Basha.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, No. 6, 01.06.2018, p. 78-87.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pharmacotherapy of heart failure

AU - Vittalrao, Amberkar Mohanbabu

AU - Thanusubramanian, Harish

AU - Meena Kumari, K.

AU - Shaik, Arshad Basha

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Heart failure (HF) is one of the major problems related to heart diseases in the modern era. Multiple comorbidities such as coronary artery disease, hypertension, diabetes mellitus, and anemia have a great contribution in the development of HF. It is primarily two types systolic and diastolic HF. Insufficient or decreased pumping of the heart is systolic HF, whereas diastolic HF is because of lack of ability of the heart to relax or increased muscle inflexibility. The pathophysiology of HF is due to enhanced activity of sympathetic system, renin angiotensin system, and structural changes in the wall of ventricle. The two definite targets of medical treatment in HF are as follows: (1) Alleviation of obstructive (or) decreased output manifestations and replenishment of cardiac function. The drugs used are frusemide, thiazides, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), amrinone/milrinone, dopamine/dobutamine, levosimendan, digoxin, hydralazine, nitroprusside, nitrate, bisoprolol, metoprolol, nebivolol, and carvedilol. (2) Prevention of advancement of HF and extension of patient survival-drugs used are β blockers, ACE inhibitors/ARBs, spironolactone, and eplerenone.

AB - Heart failure (HF) is one of the major problems related to heart diseases in the modern era. Multiple comorbidities such as coronary artery disease, hypertension, diabetes mellitus, and anemia have a great contribution in the development of HF. It is primarily two types systolic and diastolic HF. Insufficient or decreased pumping of the heart is systolic HF, whereas diastolic HF is because of lack of ability of the heart to relax or increased muscle inflexibility. The pathophysiology of HF is due to enhanced activity of sympathetic system, renin angiotensin system, and structural changes in the wall of ventricle. The two definite targets of medical treatment in HF are as follows: (1) Alleviation of obstructive (or) decreased output manifestations and replenishment of cardiac function. The drugs used are frusemide, thiazides, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), amrinone/milrinone, dopamine/dobutamine, levosimendan, digoxin, hydralazine, nitroprusside, nitrate, bisoprolol, metoprolol, nebivolol, and carvedilol. (2) Prevention of advancement of HF and extension of patient survival-drugs used are β blockers, ACE inhibitors/ARBs, spironolactone, and eplerenone.

UR - http://www.scopus.com/inward/record.url?scp=85048232654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048232654&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2018.v11i6.23712

DO - 10.22159/ajpcr.2018.v11i6.23712

M3 - Review article

VL - 11

SP - 78

EP - 87

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 6

ER -